Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.